Treatment of sepsis: current status of clinical immunotherapy - PubMed (original) (raw)
Review
Treatment of sepsis: current status of clinical immunotherapy
A O'Callaghan et al. Surgeon. 2006 Dec.
Abstract
While antibiotics address the root cause of sepsis--that of pathogen infection--they fail to provide an adequate cure for the condition. Currently, 30% to 50% of septic patients die, and this figure is likely to increase in line with the proliferation of multi-drug resistant bacteria. With an increased understanding of the immune response, it has been proposed that modulation of this defence mechanism offers the best hope of cure. Many entry-points in the immune system have been identified and targeted therapies have been developed,but why are these not in routine clinical practice? This review examines the latest evidence for the use of immuno-modulating drugs, obtained from human clinical trials. We discuss cytokine-based therapies, steroids and anti-coagulants. Finally, consideration is given as to why successful therapies in the laboratory, and in vivo models, do not automatically translate into clinical benefit
Similar articles
- [Problems and perspective approaches to correction of mediator response in sepsis].
Mironov PI, Rudnov VA. Mironov PI, et al. Anesteziol Reanimatol. 1999 May-Jun;(3):54-9. Anesteziol Reanimatol. 1999. PMID: 10458039 Review. Russian. No abstract available. - Immunotherapy of sepsis.
van der Poll T. van der Poll T. Lancet Infect Dis. 2001 Oct;1(3):165-74. doi: 10.1016/S1473-3099(01)00093-7. Lancet Infect Dis. 2001. PMID: 11871493 Review. - Targeting cytokines as a treatment for patients with sepsis: A lost cause or a strategy still worthy of pursuit?
Brown KA, Brown GA, Lewis SM, Beale R, Treacher DF. Brown KA, et al. Int Immunopharmacol. 2016 Jul;36:291-299. doi: 10.1016/j.intimp.2016.04.041. Epub 2016 May 19. Int Immunopharmacol. 2016. PMID: 27208433 Review. - Sepsis immunopathology: perspectives of monitoring and modulation of the immune disturbances.
Skirecki T, Borkowska-Zielińska U, Złotorowicz M, Hoser G. Skirecki T, et al. Arch Immunol Ther Exp (Warsz). 2012 Apr;60(2):123-35. doi: 10.1007/s00005-012-0166-1. Arch Immunol Ther Exp (Warsz). 2012. PMID: 22301668 Review.
Cited by
- The unusual antibacterial activity of medical-grade Leptospermum honey: antibacterial spectrum, resistance and transcriptome analysis.
Blair SE, Cokcetin NN, Harry EJ, Carter DA. Blair SE, et al. Eur J Clin Microbiol Infect Dis. 2009 Oct;28(10):1199-208. doi: 10.1007/s10096-009-0763-z. Epub 2009 Jun 10. Eur J Clin Microbiol Infect Dis. 2009. PMID: 19513768 - Propionibacterium acnes-killed attenuates the inflammatory response and protects mice from sepsis by modulating inflammatory factors.
Silva JB, Oliveira SK, Campos IA, Carvalho-Júnior CH, Coutinho Tda C, Silva TG. Silva JB, et al. Braz J Infect Dis. 2013 Jan-Feb;17(1):20-6. doi: 10.1016/j.bjid.2012.08.023. Epub 2013 Jan 3. Braz J Infect Dis. 2013. PMID: 23290472 Free PMC article. - Diagnostic value of serum leptin and a promising novel diagnostic model for sepsis.
Chen M, Wang B, Xu Y, Deng Z, Xue H, Wang L, He L. Chen M, et al. Exp Ther Med. 2014 Apr;7(4):881-886. doi: 10.3892/etm.2014.1506. Epub 2014 Jan 27. Exp Ther Med. 2014. PMID: 24669245 Free PMC article. - Potential of immunomodulatory host defense peptides as novel anti-infectives.
Easton DM, Nijnik A, Mayer ML, Hancock RE. Easton DM, et al. Trends Biotechnol. 2009 Oct;27(10):582-90. doi: 10.1016/j.tibtech.2009.07.004. Epub 2009 Aug 14. Trends Biotechnol. 2009. PMID: 19683819 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical